AEON Biopharma - Class A opened lower at $0.17, compared with its previous close of $0.17. In the last trading session, the stock traded between $0.16 and $0.18. It showed a downward intraday trend.
An investment of $100 made 4 years ago in AEON Biopharma - Class A is now worth
$ 0.02
Resulting in a loss of
$ 99.98 (99.98%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.01 (-5.48%)
Day High
$0.18
Day Low
$0.16
Day Open
$0.17
Prev Close
$0.17
Volume
2,40,399
1W Return
-27.35%
1M Return
-34.41%
3M Return
-41.52%
6M Return
-81.63%
1Y Return
-82.61%
Market Cap ($ Mn)
10
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
4,730.10%
EPS (TTM)
-
1 Week
-27.35%
1 Month
-34.41%
3 Months
-41.52%
6 Months
-81.63%
9 Months
-84.42%
AEON Biopharma grants 150,000 RSUs to new employee under inducement plan
AEON Biopharma granted 150,000 RSUs to a new non-executive employee. The award was approved on October 5, 2026, under the 2025 Employment Inducement Plan. RSUs vest in four equal annual installments beginning March 9, 2027. The grant complies with NYSE American LLC Company Guide Section 711 requirements.
1mo agoAEON Biopharma to host investor meetings at Lake Street’s BIG10 conference
AEON Biopharma to host one-on-one investor meetings at Lake Street’s BIG10 Conference on September 10, 2026. Company advances ABP-450 as a biosimilar to BOTOX for therapeutic use in the U.S. market. U.S. therapeutic neurotoxin market valued at over $3.0 billion annually. ABP-450 manufactured by Daewoong Pharmaceutical in FDA-authorized facility. AEON holds exclusive development and distribution rights in key international markets.
2mo agoAEON Biopharma appoints Paul Lee as acting chief regulatory officer
AEON Biopharma appoints Paul Lee as acting Chief Regulatory Officer. Lee joins via Clintrex Research LLC, an affiliate of BlueRidge Life Sciences. He will lead regulatory strategy for ABP-450, a BOTOX biosimilar. Lee brings over seven years of FDA experience in neuroscience roles.
2mo agoAEON Biopharma reports expanded structural data for ABP-450 biosimilar
AEON Biopharma has released expanded structural data for its lead asset ABP-450, confirming 98% sequence coverage and 100% amino acid identity compared to BOTOX. The preliminary disulfide bond characterization further supports molecular similarity. These findings build on previous November 2025 data and precede an expected FDA Type 2b meeting in H2 2026.
2mo agoAEON Biopharma Q2 EPS $(0.02) beats $(0.12) estimate
AEON Biopharma reported Q2 2026 EPS of $(0.02), beating estimates by 83.33%. Net loss narrowed to $1.2 million from $6.6 million YoY, driven by a $4.9 million warrant gain. The company raised $13.6 million in July, extending its cash runway into Q1 2027.
3mo agoAEON Biopharma Regains NYSE Compliance After $13.6 Million Capital Raise
AEON Biopharma has restored compliance with NYSE American’s stockholders’ equity standards after receiving $13.6 million in net proceeds from a July 2026 public offering. The capital raise allowed the company to exceed the $4.0 million minimum equity requirement, resolving prior deficiencies under Sections 1003(a)(i) and (ii) of the Company Guide and eliminating immediate delisting threats while it develops its lead asset ABP-450.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in AEON Biopharma - Class A is now worth
$ 0.02
Resulting in a loss of
$ 99.98 (99.98%)
Note: Past profits do not guarantee future returns.
